2/2 improving mobility after revascularization in peripheral artery disease: the impact pad trial - the impact pad trial DCC project summary this U24 application from the wake forest university school…
Active Cooperative Agreement Awarded Last action
- Award ID
- U24HL169563
- Recipient
-
Wake Forest University Health Sciences UEI SN7KD2UK7GC5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,017,296
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 30% complete
- Place of performance
- Winston-Salem, NC 27157, USA
Award details come from USAspending.gov.
Description
2/2 improving mobility after revascularization in peripheral artery disease: the impact pad trial - the impact pad trial DCC project summary this U24 application from the wake forest university school of medicine (wfusm) describes plans by expe- rienced investigators and staff to serve as the data coordinating center (DCC) for the improving mobility after revascularization in peripheral artery disease: the impact pad trial (impact pad), a 2 × 2 factorial n=386 trial. We will build on our successes in dozens of large, long-term trials and epidemiologic studies. Our DCC experience will help ensure success in the implementation of this trial by overseeing all data related aspects of the trial. We have a single specific aim: to provide project coordination, administration, data management, and biostatistical support for the impact pad trial. We will accomplish this by facilitating and guiding the protocol development process, providing scientifically sound study design, excellent operational and analytical methodology, a dedicated focus on recruitment, high quality follow-up and fidelity to the interventions, moni- toring safety and working with the dsmb to ensure participant safety and careful study management, working with the CCC to monitor the seven field centers, and by leading development and maintenance of the protocols, manual of procedures (mop), forms and other study documents. We believe that this trial will have nearly all the complexities of large multi-center studies, particularly for the DCC in standardization across sites. We have several strengths: (1) a team whose members are experts in the coordination of multi-center trials, including several that are ongoing, (2) experience with peripheral artery disease (pad) trials including the on- going prove trial, (3) experience with exercise trials working with the intervention proposed in this trial and nutraceuticals, (4) specific project management expertise, (5) a history of efficient and effective communication with field centers, the executive committee, and the project office, and (6) success working with DR. Mcdermott (of the CCC) on three prior studies (life, enrgise, and prove). Wfusm views clinical trial conduct and coordination as a scientific undertaking, which advances through continuous evaluation and innovation. While web-based randomized controlled trials (rcts) have been CON- ducted for over two decades, we continue to develop new and innovative strategies for integrating web-based technology into daily trial activities and incorporating other methods of electronic data capture into trial man- agement. We coordinated accord, which was the first large-scale RCT coordinated primarily over the web. The accord system has evolved into the database for efficient administration of clinical trial operations (deacon) system for web-based trial management which we use for all of our studies. We are constantly in- venting and evaluating new features to add to the deacon framework. The highly experienced and talented team at wfusm will create a state-of-the-art DCC for the impact pad trial using proven coordinating center models. Personnel will be available from day 1 and have long-standing working relationships across multiple NIH-funded studies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $618,504 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $699,396 | |
| Original award | $699,396 |
Quick answers
Who received award U24HL169563?
U24HL169563 was awarded to Wake Forest University Health Sciences by National Heart Lung and Blood Institute (National Institutes of Health) on September 17, 2024.
How much is award U24HL169563 worth?
$2,017,296 has been obligated on U24HL169563.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award